Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cilazapril is an orally active angiotensin-converting enzyme (ACE) inhibitor used primarily to treat hypertension and heart failure. It acts as a prodrug that is hydrolyzed after absorption to its active form, cilazaprilat. Cilazapril works by competitively inhibiting ACE, thereby blocking the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. This leads to decreased vasoconstriction and reduced aldosterone-mediated sodium and water reabsorption, resulting in lower blood pressure and reduced vascular resistance. Cilazapril may also be used for diabetic nephropathy to protect kidney function[1][4][5][6]. The drug has a pharmacological profile similar to other ACE inhibitors such as enalapril and ramipril[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cilazapril.